HomeCompareUGIC vs ABBV

UGIC vs ABBV: Dividend Comparison 2026

UGIC yields 12.55% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 UGIC wins by $6.0K in total portfolio value
10 years
UGIC
UGIC
● Live price
12.55%
Share price
$57.78
Annual div
$7.25
5Y div CAGR
14.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$108.3K
Annual income
$21,611.43
Full UGIC calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — UGIC vs ABBV

📍 UGIC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUGICABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UGIC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UGIC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UGIC
Annual income on $10K today (after 15% tax)
$1,066.55/yr
After 10yr DRIP, annual income (after tax)
$18,369.72/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $2,686.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UGIC + ABBV for your $10,000?

UGIC: 50%ABBV: 50%
100% ABBV50/50100% UGIC
Portfolio after 10yr
$105.3K
Annual income
$23,191.59/yr
Blended yield
22.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

UGIC
Analyst Ratings
4
Buy
2
Hold
2
Sell
Consensus: Buy
Altman Z
1.0
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UGIC buys
0
ABBV buys
0
No recent congressional trades found for UGIC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUGICABBV
Forward yield12.55%3.06%
Annual dividend / share$7.25$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR14.6%40.6%
Portfolio after 10y$108.3K$102.3K
Annual income after 10y$21,611.43$24,771.77
Total dividends collected$75.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: UGIC vs ABBV ($10,000, DRIP)

YearUGIC PortfolioUGIC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,138$1,437.95$11,550$430.00+$588.00UGIC
2$14,857$1,869.35$13,472$627.96+$1.4KUGIC
3$18,348$2,450.62$15,906$926.08+$2.4KUGIC
4$22,873$3,241.35$19,071$1,382.55+$3.8KUGIC
5$28,802$4,327.89$23,302$2,095.81+$5.5KUGIC
6$36,655$5,836.82$29,150$3,237.93+$7.5KUGIC
7$47,177$7,955.85$37,536$5,121.41+$9.6KUGIC
8$61,446$10,966.83$50,079$8,338.38+$11.4KUGIC
9$81,046$15,298.43$69,753$14,065.80+$11.3KUGIC
10$108,330$21,611.43$102,337$24,771.77+$6.0KUGIC

UGIC vs ABBV: Complete Analysis 2026

UGICStock

UGI Corporation distributes, stores, transports, and markets energy products and related services in the United States and internationally. The company operates through four segments: AmeriGas Propane, UGI International, Midstream & Marketing, and UGI Utilities. It distributes propane to approximately 1.4 million residential, commercial/industrial, motor fuel, agricultural, and wholesale customers through 1,600 propane distribution location. The company also distributes liquefied petroleum gases (LPG) to residential, commercial, industrial, agricultural, wholesale and automobile fuel customers; and provides logistics, storage, and other services to third-party LPG distributors. In addition, it engages in the retail sale of natural gas, liquid fuels, and electricity to approximately 12,600 residential, commercial, and industrial customers at 42,400 locations. Further, the company distributes natural gas to approximately 672,000 customers in eastern and central Pennsylvania counties through its distribution system of approximately 12,400 miles of gas mains; and supplies electricity to approximately 62,500 customers in northeastern Pennsylvania through 2,600 miles of lines and 14 substations. Additionally, it operates electric generation facilities, which include coal-fired, landfill gas-fueled, solar-powered, and natural gas-fueled facilities; a natural gas liquefaction, storage, and vaporization facility; propane storage and propane-air mixing stations; and rail transshipment terminals. It also manages natural gas pipeline and storage contracts; develops, owns, and operates pipelines, gathering infrastructure, and gas storage facilities. UGI Corporation was incorporated in 1991 and is based in King of Prussia, Pennsylvania.

Full UGIC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this UGIC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UGIC vs SCHDUGIC vs JEPIUGIC vs OUGIC vs KOUGIC vs MAINUGIC vs JNJUGIC vs MRKUGIC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.